Diabetic nephropathy: what should cardiologist remember

Cover Page

Cite item

Full Text

Abstract

Prevalence of diabetes mellitus (DM) progressively increases around the world. Diabetic nephropathy (DN) is significant reason of end-stage renal disease and it is associated with high risk of cardiovascular disease and mortality. Necessity of expensive renal replacement therapy for patients with prominent vascular diabetic complications and end-stage renal disease has significant socio-economic impact. DM, as a one of leading causes of kidney diseases, competes for stricted resources of public health. Renal replacement therapy in patients with DM does not solve the whole problem, because survival of such patients is low, comparing with another kidney diseases, first of all because of cardiovascular diseases. Good control of glycaemia, blood pressure and cholesterol level and prescription of renin-angiotensin-aldosterone system inhibitors and statins decrease cardiovascular risk and slow down DN progression, as it was shown in many clinical trials. So patients with DM and DN should receive complex therapy for risk reduction of kidney disease and cardiovascular disorders progression.

About the authors

Natalia P. Trubitsyna

Endocrinology Research Centre

Email: trubicina@mail.ru
канд. мед. наук, вед. науч. сотр. Moscow, Russia

Natalia V. Zaitseva

Endocrinology Research Centre

канд. мед. наук, вед. науч. сотр. Moscow, Russia

Anastasia S. Severine

Endocrinology Research Centre

канд. мед. наук, вед. науч. сотр. Moscow, Russia

References

  1. Williams R, Colagiuri S, Almutairi R, et al. IDF Diabetes Atlas 2019; 9: 2.
  2. Hill NR, Fatoba ST, Oke JL, et al. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One. 2016; 6: 1-2. doi: 10.1371/journal.pone.0158765
  3. Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020; 395 (10225): 709-33. doi: 10.1016/S0140-6736(20)30045-3
  4. Мартынов С.А., Северина А.С., Ларина И.И., и др. Подготовка пациента с сахарным диабетом 1 типа на заместительной почечной терапии диализом к трансплантации почки. Проблемы эндокринологии. 2020; 66 (6): 18-30. doi: 10.14341/probl12686
  5. Johnstone MT, Veves A. Diabetes and Cardiovascular Disease. Humana Press, 2005. doi: 10.1385/1592599087
  6. Шестакова М.В., Викулова О.К., Железнякова А.В., и др. Эпидемиология сахарного диабета в Российской Федерации: что изменилось за последнее десятилетие? Терапевтический архив. 2019; 91 (10): 4-13
  7. Tonneijck L, Muskiet MH, Smits MM, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol 2017; 28 (4): 1023-39. doi: 10.1681/ASN.2016060666
  8. Szeto CC, Kwan BC, Lai KB, et al. Urinary expression of kidney injury markers in renal transplant recipients. Clin J Am Soc Nephrol 2010; 5 (12): 2329-37. doi: 10.2215/CJN.01910310
  9. Valmadrid CT, Klein R, Moss SE, Klein BEK. Disease Mortality Associated With Microalbuminuria and Gross Proteinuria in Persons With Older-Onset Diabetes Mellitus. Arch Intern Med 2000; 160 (8): 1093-100. doi: 10.1001/archinte.160.8.1093
  10. Collins AJ, Foley RN, Herzog C, et al. US Renal Data System 2010 Annual Data Report. Am J Kidney Dis 2011; 57 (1): 1-526. doi: 10.1053/j.ajkd.2010.10.007
  11. Bakris GL, Serafidis PA, Weir MR, et al. ACCOMPLISH Trial Investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH) a prespecified secondary analysis of randomised controlled trial. Lancet 2010 (375): 1173-81. doi: 10.1016/S0140-6736(09)62100-0
  12. Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367 (24): 2296-304. doi: 10.1056/NEJMoa1210357
  13. Моисеев В.С., Мухин Н.А., Смирнов А.В. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Российский кардиологический журнал. 2014; 8 (112): 7-37
  14. Nathan DM. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care 2014; 37 (1): 9-16. doi: 10.2337/dc13-2112
  15. Hayes AJ, Leal J, Gray AM, et al. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 2013; 56 (9): 1925-33. doi: 10.1007/s00125-013-2940-y
  16. Hirakawa Y, Arima H, Zoungas S, et al. Impact of visit-tovisit glycemic variability on the risks of mac-rovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care 2014; 37 (8): 2359-65. doi: 10.2337/dc14-0199
  17. Дедов И.И., Шестакова М.В., Майоров А.Ю. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Сахарный диабет. 2019; 22 (1): 1-144
  18. Robinson TW, Freedman BI. Assessing glycemic control in diabetic patients with severe nephropathy. J Ren Nutr 2013; 23: 199. doi: 10.1053/j.jrn.2013.01.021
  19. Alsahli M, Gerich JE. Hypoglycemia in Patients with Diabetes and Renal Disease. J Clin Med 2015; 4 (5): 948-64. doi: 10.3390/jcm4050948
  20. Triggle CR, Ding H. Cardiovascular impact of drugs used in the treatment of diabetes. Ther Adv Chro nic Dis 2014; 5 (6): 245-68. doi: 10.1177/2040622314546125
  21. Takiyama Y, Harumi T, Watanabe J, et al. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1a expression and oxygen metabolism. Diabetes 2011; 60 (3): 981-92. doi: 10.2337/db10-0655
  22. Seo-Mayer PW, Thulin G, Zhang L, et al. Preactivation of AMPK by metformin may ameliorate the epithelial cell damage caused by renal ischemia. Am J Physiol Renal Physiol 2011; 301 (6): 134657. doi: 10.1152/ajprenal.00420.2010
  23. Mita T, Katakami N, Shiraiwa T, et al. Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the sitagliptin preventive study of intimamedia thickness evaluation (SPIKE): a randomized controlled trial. Diabetes Care 2016; 39 (3): 45564. doi: 10.2337/dc15-2145
  24. Рабочая группа по сахарному диабету, предиабету и сердечно-сосудистым заболеваниям Европейского общества кардиологов (ESC, ЕОК) и Европейской ассоциации по изучению сахарного диабета (EASD, ЕАСД). 2019 Рекомендации ESC/EASD по сахарному диабету, предиабету и сердечно-сосудистым заболеваниям. Российский кардиологический журнал. 2020; 25 (4): 3839
  25. Багрий А.Э., Супрун Е.В., Михайличенко Е.С., Голодников И.А. Хроническая сердечная недостаточность и сахарный диабет 2 типа: состояние проблемы. Российский кардиологический журнал. 2020; 25 (4): 84
  26. Сидоров А.В. Клиническая фармакология ингибиторов дипептидилпептидазы 4: сравнительный обзор. Эффективная фармакотерапия. 2020; 16 (25): 24-48
  27. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014; 2 (5): 369-84. doi: 10.1016/S2213-8587(13)70208-0
  28. Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 2014; 306 (2): 194-204. doi: 10.1152/ajprenal.00520.2013
  29. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129: 587-97. doi: 10.1161/CIRCULATIONAHA.113.005081
  30. Wanner C, Lachin JM, Inzucchi SE, et al.; EMPA-REG OUTCOME^nvestigators. Empagliflozin and Clinical Outcomes in Patients with Type 2 Diabetes, Established Cardiovascular Disease and Chronic Kidney Disease. Circulation 2018; 137 (2): 119-29. doi: 10.1161/CIRCULATIONAHA.117.028268
  31. Кобалава Ж.Д., Лазарев П.В., Виллевальде С.В. Ингибиторы SGLT2: обоснование и перспективы применения при сердечной недостаточности. Кардиология. 2018; 58 (2): 42-54
  32. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377 (7): 644-57. doi: 10.1056/NEJMoa1611925
  33. Neeland IJ, McGuire DK, Chilton R, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diabetes Vasc Dis Res 2016; 13: 119-26. doi: 10.1177/1479164115616901
  34. Greco EV, Russo G, Giandalia A, et al. GLP-1 receptor agonist and kidney protection. Medicina 2019; 55: 233. doi: 10.3390/medicina55060233
  35. Skov J, Dejgaard A, Frokiaer J, et al. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab 2013; 98 (4): E664-E671. doi: 10.1210/jc.2012-3855
  36. Gutzwiller JP, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004; 89 (6): 3055-61. doi: 10.1210/jc.2003-031403
  37. Asmar A, Simonsen L, Asmar M, et al. Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. Am J Physiol Endocrinol Metab 2015; 308 (8): E641-9. doi: 10.1152/ajpendo.00429.2014
  38. Аметов А.С., Невольникова А.О., Тертычная Е.А. Возможности агонистов рецепторов глюкагоноподобного пептида-1 в снижении сердечно-сосудистого риска у пациентов с сахарным диабетом типа 2: что нового? Эндокринология: новости, мнения, обучение. 2019; 8 (3): 44-53
  39. Шамхалова М.Ш., Скляник И.А., Шестакова М.В. Нефропротективный потенциал агонистов рецепторов глюкагоноподобного пептида 1. Сахарный диабет. 2020; 23 (1): 56-64
  40. Ярек-Мартынова И.Р., Шамхалова М.Ш. Органопротективные эффекты блокаторов рецепторов ангиотензина II у больных сахарным диабетом 2 типа. Сахарный диабет. 2010; 2: 58-61
  41. Шамхалова М.Ш., Трубицына Н.П., Шестакова М.В. Феномен частичного ускользания блокады ангиотензина II у больных сахарным диабетом 2 типа и диабетической нефропатией. Терапевтический архив. 2008; 80 (1): 49-52
  42. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345 (12): 851-60. doi: 10.1056/NEJMoa011303
  43. Haller H, Ito S, Izzo JL Jr, et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-17. doi: 10.1056/NEJMoa1007994
  44. Moorhead JF Lipids and the pathogenesis of kidney disease. Am J Kidney Dis 1991; 27 (1): 65-70. doi: 10.1159/000127980
  45. Scheuer H, Gwinner W, Holbach J, et al. Oxidant stress in hyperlipidemia induced renal damage. Am J Physiol 2000 (278): 63-74. doi: 10.1152/ajprenal.2000.278.1.F63
  46. Abrass OK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 2004 (24): 46-53. doi: 10.1159/000075925
  47. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. Вып. 9. Сахарный диабет. 2019 (22): 1144

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies